Nasdaq issues noncompliance letter to Altus Pharmaceuticals

Altus Pharmaceuticals Inc. (Nasdaq: ALTU) today announced that on September 15, 2009, the Company received a letter from the Nasdaq Listing Qualifications Department notifying the Company that, for the last 30 consecutive business days, the bid price of the Company’s common stock has closed below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Company’s shares will continue to trade on the Nasdaq Capital Market under the symbol “ALTU.”

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq will provide the Company with 180 calendar days, or until March 15, 2010, to regain compliance. If at any time before March 15, 2010 the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with Nasdaq Listing Rule 5550(a)(2). If the Company does not meet this requirement, the Company’s common stock may be delisted.

In addition, in light of the Company’s disclosure that it has commenced a process to wind down the business of the Company, the Company received a letter from Nasdaq on September 16, 2009 requesting the Company to supply certain information in order to enable Nasdaq to determine whether the Company may be deemed a “public shell.” If Nasdaq determines that the Company is a “public shell”, Nasdaq may, under Nasdaq Listing Rule 5100, determine to delist the Company’s common stock, even if the Company regains compliance with the minimum bid price rule.